Current Treatments in Mantle Cell Lymphoma

Research output: Contribution to journalReview articlepeer-review

Abstract

Mantle cell lymphoma (MCL) is characterized by heterogeneous biology and varied clinical presentations. Historically, it has been associated with a poor prognosis when compared with other non-Hodgkin lymphomas. With a better understanding of the disease biology, molecular pathogenesis, and new treatments, the outcomes have been gradually improving. Identification of high-risk mutations has resulted in better prognostication and paved the way for risk-adapted treatment approaches. Although chemoimmunotherapy remains the mainstay frontline treatment, combination therapies incorporating novel agents such as Bruton tyrosine kinase inhibitors, B-cell lymphoma inhibitors, and immunomodulatory agents are being studied, with promising results. Chimeric antigen receptor T-cell therapy and bispecific T-cell engagers have opened a new avenue for treatment. Also promising are antibody-drug conjugates such as ROR1 inhibitors and PI3K inhibitors, which are under clinical investigation. We provide an overview of the molecular mutations identified in MCL and the evolving treatment strategies for this disease.

Original languageEnglish (US)
Pages (from-to)326-332
Number of pages7
JournalONCOLOGY (United States)
Volume37
Issue number8
DOIs
StatePublished - Aug 16 2023

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Fingerprint

Dive into the research topics of 'Current Treatments in Mantle Cell Lymphoma'. Together they form a unique fingerprint.

Cite this